LEADER 04382nam 2200589 450 001 9910463038703321 005 20200311153802.0 010 $a1-912530-37-6 010 $a1-908230-85-1 035 $a(CKB)2670000000427609 035 $a(EBL)1938095 035 $a(SSID)ssj0001127788 035 $a(PQKBManifestationID)11634202 035 $a(PQKBTitleCode)TC0001127788 035 $a(PQKBWorkID)11151873 035 $a(PQKB)10001358 035 $a(MiAaPQ)EBC1938095 035 $a(MiAaPQ)EBC6031536 035 $a(Au-PeEL)EBL6031536 035 $a(OCoLC)880720215 035 $a(EXLCZ)992670000000427609 100 $a20200311d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCytomegaloviruses$hVolume II $efrom molecular pathogenesis to intervention /$fedited by Matthias J. Reddehase ; with the assistance of Niels A.W. Lemmermann 210 1$aNorfolk, England :$cCaister Academic Press,$d[2013] 210 4$dİ2013 215 $a1 online resource (559 p.) 300 $aDescription based upon print version of record. 311 $a1-908230-20-7 320 $aIncludes bibliographical references and indexes. 327 $aContents Volume II; Abbreviations used in Volume II; Ch II.1: Synopsis of Clinical Aspects of Human Cytomegalovirus Disease; Ch II.2: The Epidemiology and Public Health Impact of Congenital Cytomegalovirus Infection; Ch II.2 - Addendum: The Economic Impact of Congenital CMV Infection: Methods and Estimates; Ch II. 3: Clinical Cytomegalovirus Research: Congenital Infection; Ch II. 4: Cytomegalovirus Replication in the II.4Developing Human Placenta; Ch II.5: The Guinea Pig Model of Congenital Cytomegalovirus Infection; Ch II. 6: Murine Model of Neonatal Cytomegalovirus Infection 327 $aCh II.7: Adaptive Cellular Immunity to Human II.7CytomegalovirusCh II.8: Natural Killers Cells and Human Cytomegalovirus; Ch II.9: Innate Immunity to Cytomegalovirus in the Murine Model; Ch II.10: Protective Humoral Immunity; Ch II.11: Immunoregulatory Cytokine Networks Discovered and Characterized during Murine Cytomegalovirus Infections; Ch II.12: Host Genetic Models in Cytomegalovirus Immunology; Ch II.13: Clinical Cytomegalovirus Research: Thoracic Organ Transplantation; Ch II.14: Clinical Cytomegalovirus Research: Liver and Kidney Transplantation 327 $aCh II.15: The Rat Model of Cytomegalovirus Infection and Vascular DiseaseCh II.16: Clinical Cytomegalovirus Research: Haematopoietic Cell Transplantation; Ch II.17: Murine Model for Cytoimmunotherapy of CMV Disease after Haematopoietic Cell Transplantation; Ch II.18: State of the Art and Trends in Cytomegalovirus Diagnostics; Ch II.19: Antiviral Therapy, Drug Resistance and Computed Resistance Profiling; Ch II 20: Cytomegalovirus Vaccine: On the Way to the Future?; Ch II.21: Vaccine Vectors Using the Unique Biology and Immunology of Cytomegalovirus 327 $aCh II.22: Non-Human-Primate Models of Cytomegalovirus Infection, Prevention, and TherapyCh II. 23: Putative Disease Associations with Cytomegalovirus: a Critical Survey; Epilogue - Re?sume? and Visions: From CMV Todayto CMV Tomorrow; Subject index; Open reading frame index; Cluster of differentiation index; CMV strains index; Antiviral drugs index; Frequently discussed molecules 330 $aHuman Cytomegalovirus (CMV) - a member of the herpesvirus family - is an underrated health risk. A low public awareness results from the relatively mild symptoms it causes in otherwise healthy people whose immune systems are intact, with primary infection usually going unnoticed. During pregnancy, however, transmission from the mother to the fetus is currently the most frequent viral cause of birth defects with lifelong neurological sequelae, sensorineural hearing loss in particular. People at risk also include the growing number of immune compromised patients requiring either a solid organ gr 606 $aCytomegalovirus infections 608 $aElectronic books. 615 0$aCytomegalovirus infections. 676 $a616.925 702 $aReddehase$b Matthias J. 702 $aLemmermann$b Niels 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910463038703321 996 $aCytomegaloviruses$92138481 997 $aUNINA